Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Unknown 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 50Carcinoma, Non-Small-Cell Lung 39Carcinoma, Renal Cell 28Carcinoma, Hepatocellular 18Neoplasm Metastasis 16Neoplasms 15Colorectal Neoplasms 15Stomach Neoplasms 13Lung Neoplasms 13Adenocarcinoma Of Esophagus 11Squamous Cell Carcinoma of Head and Neck 10Carcinoma, Transitional Cell 8Brain Neoplasms 8Hodgkin Disease 7Skin Neoplasms 6Sarcoma 6Kidney Neoplasms 6Esophageal Neoplasms 6Triple Negative Breast Neoplasms 5Prostatic Neoplasms 5Pancreatic Neoplasms 5Clear-cell metastatic renal cell carcinoma 5Carcinoma, Merkel Cell 5Uveal Melanoma 4Uterine Cervical Neoplasms 4Urinary Bladder Neoplasms 4Recurrence 4Neuroendocrine Tumors 4Nasopharyngeal Carcinoma 4Mesothelioma 4

Interventions

Drug Therapy 2trastuzumab deruxtecan 1spartalizumab 1sacituzumab govitecan 1Radiotherapy 1Nivolumab 1Interleukin-2 1Fecal Microbiota Transplantation 1Docetaxel 1Cyclophosphamide 1Cisplatin 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Drug-Related Side Effects and Adverse Reactions × Nivolumab × Clear all
NCT05652673 2025-02-28

Safe Stop Ipilimumab-nivolumab (IPI-NIVO) Trial

Erasmus Medical Center

Phase NA Recruiting
80 enrolled
Dermatologic

Melanoma, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡